Rapid Novor is committed to advancing human health with their world-leading antibody protein sequencing technology. Their first blood-based biopsy reliably screens for M-proteins, detecting relapse in multiple myeloma patients more than half a year earlier than traditional invasive methods. Their REmAb™ protein sequencing platform incorporates state-of-the-art machine learning algorithms with high-throughput mass spectrometry-based proteomics to accurately derive protein sequences.